心房颤动老年患者口服抗凝药与衰弱、居家时间及医疗费用
该社区队列研究纳入2013年1月1日至2019年12月31日65岁及以上房颤的 Medicare 按服务收费受益人,比较阿哌沙班、利伐沙班和 warfarin 的居家时间、临床事件和费用。倾向评分重叠加权后共136551人(阿哌沙班45950人、利伐沙班45320人、warfarin 45281人)。与阿哌沙班相比,利伐沙班居家时间丢失>14天的风险每100人增加1.8(95%CI 1.5-2.1),复合终点每1000人年增加21.3(95%CI 16.4-26.2),总费用平均增加890美元(95%CI 652-1127),衰弱者差异更大。与阿哌沙班相比,warfarin 居家时间丢失每100人增加3.2(95%CI 2.9-3.5),复合终点每1000人年增加29.4(95%CI 24.5-34.3),总费用平均降低1166美元(95%CI -1396至-937),但排除抗凝药费用后费用平均增加1409美元(95%CI 1177-1642),且不受衰弱水平影响。
要点
- 与阿哌沙班相比,利伐沙班居家时间丢失>14天的风险每100人增加1.8(95%CI 1.5-2.1),复合终点每1000人年增加21.3(95%CI 16.4-26.2),总费用平均增加890美元(95%CI 652-1127)。
- 与阿哌沙班相比,warfarin 居家时间丢失每100人增加3.2(95%CI 2.9-3.5),复合终点每1000人年增加29.4(95%CI 24.5-34.3)。
- 阿哌沙班较利伐沙班和 warfarin 的居家时间与临床事件优势在衰弱受益人中最明显。
- 与阿哌沙班相比,warfarin 总费用平均降低1166美元(95%CI -1396至-937),但排除抗凝药费用后费用平均增加1409美元(95%CI 1177-1642),不受衰弱水平影响。
- 作者认为,阿哌沙班可能更适用于老年房颤患者,尤其是衰弱者。
适用人群与场景
- 2013年1月1日至2019年12月31日65岁及以上、参加 Medicare 按服务收费的房颤患者。
诊断标准与关键阈值
- 衰弱采用经过验证的、基于理赔数据的衰弱指数评估。
- 居家时间定义为存活且不在医院和专业护理机构的天数,居家时间丢失>14天为结局指标。
处置流程与药物剂量
- 暴露药物为阿哌沙班、利伐沙班和 warfarin,依据处方理赔记录判定。
研究设计与关键结果
- 研究为社区队列研究,加权后共纳入136551名受益人:阿哌沙班45950人(平均[SD]年龄77.6[7.3]岁,女性51.3%),利伐沙班45320人(平均[SD]年龄77.6[7.3]岁,女性51.9%),warfarin 45281人(平均[SD]年龄77.6[7.3]岁,女性52.0%)。
- 与阿哌沙班相比,利伐沙班与居家时间丢失>14天风险升高相关(每100人风险差1.8,95%CI 1.5-2.1),复合终点升高(每1000人年率差21.3,95%CI 16.4-26.2),总费用升高(平均差890美元,95%CI 652-1127),衰弱者差异更大。
- 与阿哌沙班相比,warfarin 与居家时间丢失增加(每100人风险差3.2,95%CI 2.9-3.5)和复合终点增加(每1000人年率差29.4,95%CI 24.5-34.3)相关,衰弱者差异更大。
- 与阿哌沙班相比,warfarin 总费用更低(平均差-1166美元,95%CI -1396至-937),但排除抗凝药费用后费用更高(平均差1409美元,95%CI 1177-1642),且不受衰弱水平影响。
证据类型、等级与局限
- 证据类型:社区队列研究。
对床旁实践的改变
- 在老年房颤患者中,阿哌沙班与利伐沙班和 warfarin 相比与更多居家时间和更低临床事件率相关,衰弱者中差异更大。
- 作者认为,阿哌沙班可能更适用于老年房颤患者,尤其是衰弱者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: There are no data on patient-centered outcomes and health care costs by frailty in patients with atrial fibrillation (AF) taking oral anticoagulants (OACs).
OBJECTIVE: To compare home time, clinical events, and health care costs associated with OACs by frailty levels in older adults with AF.
DESIGN, SETTING, AND PARTICIPANTS: This community-based cohort study assessed Medicare fee-for-service beneficiaries 65 years or older with AF from January 1, 2013, to December 31, 2019. Data analysis was performed from January to December 2022.
EXPOSURES: Apixaban, rivaroxaban, and warfarin use were measured from prescription claims. Frailty was measured using a validated claims-based frailty index.
MAIN OUTCOMES AND MEASURES: Outcome measures were (1) home time (days alive out of the hospital and skilled nursing facility) loss greater than 14 days; (2) a composite end point of ischemic stroke, systemic embolism, major bleeding, or death; and (3) total cost per member per year after propensity score overlap weighting.
RESULTS: The weighted population comprised 136 551 beneficiaries, including 45 950 taking apixaban (mean [SD] age, 77.6 [7.3] years; 51.3% female), 45 320 taking rivaroxaban (mean [SD] age, 77.6 [7.3] years; 51.9% female), and 45 281 taking warfarin (mean [SD] age, 77.6 [7.3] years; 52.0% female). Compared with apixaban, rivaroxaban was associated with increased risk of home time lost greater than 14 days (risk difference per 100 persons, 1.8 [95% CI, 1.5-2.1]), composite end point (rate difference per 1000 person-years, 21.3 [95% CI, 16.4-26.2]), and total cost (mean difference, $890 [95% CI, $652-$1127]), with greater differences among the beneficiaries with frailty. Use of warfarin relative to apixaban was associated with increased home time lost (risk difference per 100 persons, 3.2 [95% CI, 2.9-3.5]) and composite end point (rate difference per 1000 person-years, 29.4 [95% CI, 24.5-34.3]), with greater differences among the beneficiaries with frailty. Compared with apixaban, warfarin was associated with lower total cost (mean difference, -$1166 [95% CI, -$1396 to -$937]) but higher cost when excluding OAC cost (mean difference, $1409 [95% CI, $1177 to $1642]) regardless of frailty levels.
CONCLUSIONS AND RELEVANCE: In older adults with AF, apixaban was associated with increased home time and lower rates of clinical events than rivaroxaban and warfarin, especially for those with frailty. Apixaban was associated with lower total cost compared with rivaroxaban but higher cost compared with warfarin due to higher OAC cost. These findings suggest that apixaban may be preferred for older adults with AF, particularly those with frailty.
参考来源
- Lin KJ, Singer DE, Ko D, et al. Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral Anticoagulants. JAMA Netw Open. 2023. PMID: 37943558. doi:10.1001/jamanetworkopen.2023.42264
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。